Almost 98% of the genome does not encode proteins. Recent advances in next-generation sequencing technologies, particularly RNA sequencing (RNA-Seq), have made it possible to study non-coding RNAs (ncRNAs). Long-stranded non-coding (LncRNA) is one of the most abundant RNA types in the non-coding genome and has become a powerful regulator of almost all biological processes. Due to their complex tertiary structure, lncRNAs may interact with RNA, DNA or proteins to control transcriptional, epigenetic or translational responses. To date, extensive studies in almost every disease model have highlighted their important role in regulating gene expression and key signaling pathways. A growing number of studies have revealed novel lncRNA-mediated regulation of cardiovascular disease (CVD) associated genes, signaling pathways and pathophysiological responses.

Fig. 1. Selection of lncRNAs involved in cardiac injury and remodelling, endothelial cell biology and angiogenesis, vascular smooth muscle cell proliferation, leukocytes and inflammation, and lipid metabolism. (Haemmig S, et al., 2017)

Customized Services

Interestingly, lncRNAs become central to the formation of liquid-liquid phase separation (LLPS) droplets when stress occurs. Many lncRNAs have been reported to be closely associated with CVD. LncRNAs may contribute to the formation of phase separation cores in CVD, and may also serve as auxiliary tools to facilitate the formation of other phase separations. CD BioSciences provides professional services to analyze the role of LLPS-mediated lncRNAs in CVD, with a particular focus on cell types associated with cardiac injury and remodeling, vascular injury, angiogenesis, inflammation, and lipid metabolism related cell types.

Our technical team has developed well-established in vitro, self-patient studies and animal translational models for the characterization of several lncRNAs from different classes, including ANRIL, MALAT, MIAT, Braveheart, Upperhand, Myheart, H19, Meg3, HOTAIR, Kcnq1ot1, CARL, SENCR, SMILR, and CARMEN, etc. What attracts customers is that we can enable targeted knockdown and fine-grained genetic manipulation of most of the lncRNA motifs involved, and study the effects on CVD in animal CVD models. In addition, we offer cutting-edge single-cell technology and CRISPR/Cas9-based genome-wide screens for genome-wide studies of lncRNAs, to help our clients analyze and identify lncRNA phase separation in CVD.

Some lncRNAs have shown therapeutic potential to improve the function of cardiomyocytes, endothelial cells or vascular smooth cells in the heart and vascular system. Our experts are committed to developing lncRNA-based therapeutic strategies for CVD, including:

• LncRNA-dependent spatial compartmentalization and nuclear scaffolding.
• Non-chemoattractive amplification of lncRNA function.
• LncRNA splice isoforms.
• LncRNA-modified functions.
• LncRNAs can express micropeptides.

Based on our advanced high-throughput lncRNAs expression analysis technology, gene microarray technology, interaction analysis and quantitative modeling of RNA-dependent gene regulatory networks, CD BioSciences aims to provide you with a comprehensive analysis of the role of lncRNAs mediated by LLPS in the cardiovascular system and to develop new targets for the prevention and treatment of CVD. Our services are widely used in preclinical research in cardiovascular disease biology, diagnosis and treatment. If you are interested in our services, please feel free to contact us.